Altimmune ( ($ALT) ) has released its Q2 earnings. Here is a breakdown of the information Altimmune presented to its investors. Altimmune, Inc. is ...

National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise ...

Altimmune (NASDAQ:ALT) shares surge 8% post-promising Q2 results, driven by pemvidutide's success in metabolic and liver conditions. Read more here.

UC Davis Health researchers have discovered that a natural molecule made by gut bacteria can reverse liver damage and repair ...

UC Davis Health researchers have discovered that a natural molecule made by gut bacteria can reverse liver damage and repair ...

Below are the transcripts from the Q2 earnings call. This transcript is brought to you by Benzinga APIs. For real-time access ...

GAITHERSBURG, Md., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic ...

A new study of liver cancer shows three ways to reduce the risk in the majority of cases. We learn more about what they are and what else the study found.

DelveInsight's THR-β Agonist Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Liver cancer is the sixth most common cancer in the world, with around 870,000 cases in 2022. That’s projected to increase to 1.52 million cases in 2050, the new report found, if no changes are ...